Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.
2.
3.
4.

A high throughput screening assay to screen for CYP2E1 metabolism and inhibition using a fluorogenic vivid p450 substrate.

Marks BD, Smith RW, Braun HA, Goossens TA, Christenson M, Ozers MS, Lebakken CS, Trubetskoy OV.

Assay Drug Dev Technol. 2002 Nov;1(1 Pt 1):73-81.

PMID:
15090158
5.

Reconstitution premixes for assays using purified recombinant human cytochrome P450, NADPH-cytochrome P450 reductase, and cytochrome b5.

Shaw PM, Hosea NA, Thompson DV, Lenius JM, Guengerich FP.

Arch Biochem Biophys. 1997 Dec 1;348(1):107-15.

PMID:
9390180
6.

In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies.

Wang L, Zhang D, Raghavan N, Yao M, Ma L, Frost CE, Maxwell BD, Chen SY, He K, Goosen TC, Humphreys WG, Grossman SJ.

Drug Metab Dispos. 2010 Mar;38(3):448-58. doi: 10.1124/dmd.109.029694. Epub 2009 Nov 25. Erratum in: Drug Metab Dispos. 2010 May;38(5):887. Frost, Charles A [corrected to Frost, Charles E].

7.

Luminogenic cytochrome P450 assays.

Cali JJ, Ma D, Sobol M, Simpson DJ, Frackman S, Good TD, Daily WJ, Liu D.

Expert Opin Drug Metab Toxicol. 2006 Aug;2(4):629-45. Review.

PMID:
16859410
8.

Development of a fluorescence-based, ultra high-throughput screening platform for nanoliter-scale cytochrome p450 microarrays.

Sukumaran SM, Potsaid B, Lee MY, Clark DS, Dordick JS.

J Biomol Screen. 2009 Jul;14(6):668-78. doi: 10.1177/1087057109336592. Epub 2009 Jun 12.

PMID:
19525490
9.

High-throughput screening assays for the assessment of CYP2C9*1, CYP2C9*2, and CYP2C9*3 metabolism using fluorogenic Vivid substrates.

Marks BD, Thompson DV, Goossens TA, Trubetskoy OV.

J Biomol Screen. 2004 Aug;9(5):439-49.

PMID:
15296644
10.

Human cytochrome p450 enzymes of importance for the bioactivation of methyleugenol to the proximate carcinogen 1'-hydroxymethyleugenol.

Jeurissen SM, Bogaards JJ, Boersma MG, ter Horst JP, Awad HM, Fiamegos YC, van Beek TA, Alink GM, Sudhölter EJ, Cnubben NH, Rietjens IM.

Chem Res Toxicol. 2006 Jan;19(1):111-6.

PMID:
16411663
11.

In vitro drug interactions of cytochrome p450: an evaluation of fluorogenic to conventional substrates.

Cohen LH, Remley MJ, Raunig D, Vaz AD.

Drug Metab Dispos. 2003 Aug;31(8):1005-15.

12.

Fluorometric high-throughput screening for inhibitors of cytochrome P450.

Miller VP, Stresser DM, Blanchard AP, Turner S, Crespi CL.

Ann N Y Acad Sci. 2000;919:26-32.

PMID:
11083094
13.

Inhibition of CYP3A4 in a rapid microtiter plate assay using recombinant enzyme and in human liver microsomes using conventional substrates.

Nomeir AA, Ruegg C, Shoemaker M, Favreau LV, Palamanda JR, Silber P, Lin CC.

Drug Metab Dispos. 2001 May;29(5):748-53.

14.
15.

Effects of ginseng components on c-DNA-expressed cytochrome P450 enzyme catalytic activity.

Henderson GL, Harkey MR, Gershwin ME, Hackman RM, Stern JS, Stresser DM.

Life Sci. 1999;65(15):PL209-14.

PMID:
10574228
17.

Coumarin substrates for cytochrome P450 2D6 fluorescence assays.

Nakamura K, Hanna IH, Cai H, Nishimura Y, Williams KM, Guengerich FP.

Anal Biochem. 2001 May 15;292(2):280-6.

PMID:
11355862
18.
20.

Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes.

Yamazaki H, Guo Z, Persmark M, Mimura M, Inoue K, Guengerich FP, Shimada T.

Mol Pharmacol. 1994 Sep;46(3):568-77.

PMID:
7935340
Items per page

Supplemental Content

Write to the Help Desk